Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2024 00:45 ET | Source: Novartis Pharma AG

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA...
December 29, 2024 19:00 ET | Source: Wisekey International Holding Ltd.

WISeKey’s Subsidiary SEALCOIN 2025 Roadmap: Leading Machine-to-Machine Transactions Through Blockchain and Space Innovation

WISeKey’s Subsidiary SEALCOIN 2025 Roadmap: Leading Machine-to-Machine Transactions Through Blockchain and Space Innovation Zug, Switzerland — December 30, 2024 - WISeKey International Holding Ltd...
December 23, 2024 03:00 ET | Source: Kuntarahoitus Oyj

Kuntarahoitus Oyj:n ennenaikaisesti eräännyttämä joukkovelkakirja on poistettu pörssilistalta

Kuntarahoitus OyjPörssitiedote23.12.2024 klo 10.00 Kuntarahoitus Oyj:n ennenaikaisesti eräännyttämä joukkovelkakirja on poistettu pörssilistalta Kuntarahoitus Oyj ilmoitti 9.12.2024 käyttävänsä...
December 23, 2024 03:00 ET | Source: Municipality Finance Plc

The notes redeemed by Municipality Finance have been removed from trading at Nasdaq Helsinki

Municipality Finance PlcStock exchange release 23 December 2024 at 10:00 am (EET) The notes redeemed by Municipality Finance have been removed from trading at Nasdaq Helsinki On 9 december 2024...
December 23, 2024 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamentenkandidaten einer neuen Antibiotika-Wirkstoffklasse

Zusätzliche finanzielle Förderung aufgrund erfolgreicher Nominierung eines WirkstoffkandidatenUSD 7.3 Mio. zur Unterstützung der Entwicklung des Antibiotikums BAL2420 (LptA-Inhibitor) hin zu ersten...
December 23, 2024 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc...
December 20, 2024 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera gibt die Zulassung von AGAMREE® (Vamorolon) zur Behandlung von Duchenne-Muskeldystrophie in Hongkong bekannt

Die Gesundheitsbehörde (Department of Health, DoH) von Hongkong hat AGAMREE® für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 4 Jahren zugelassen Vor kurzem hat China’s National...
December 20, 2024 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National...
December 20, 2024 01:00 ET | Source: Idorsia Pharmaceuticals Ltd

Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan

Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company’s...
December 19, 2024 23:05 ET | Source: Temenos

Temenos désigné Leader des plateformes de traitement bancaire numérique par un organisme de recherche indépendant

GRAND-LANCY, Suisse, 20 déc. 2024 (GLOBE NEWSWIRE) -- Temenos (SIX : TEMN) annonce aujourd’hui sa nomination en tant que Leader dans le rapport The Forrester Wave™: Digital Banking Processing...